Allergy

The authors are optimistic that this method can be replicated to identify other allergens that manifest into eosinophilic esophagitis (EoE).

Intranasal epinephrine spray offers a needle-free option for anaphylaxis treatment.

The monoclonal antibody demonstrates the ability to reduce the incidence and improve symptoms related to sleep disorders and psychiatric disorders such as anxiety.

Knowing which patients are at higher risk for developing urticaria by analyzing their history of food allergies could lead to better outcomes in this population.

Proven effective in the treatment of atopic dermatitis (AD) and other allergic conditions, these study results confirm the ability of dupilumab to improve symptoms in children with other concurrent conditions.

Prevalence increased across all subgroups among children and adolescents, with decreases observed in young adults and elderly populations.

The study also found that HSSPs minimize health costs and provide additional revenue for health systems.

Exposure to pollutants PM2.5 and NO2 was found to increase the likelihood of developing a peanut allergy and of the allergy persisting.

When compared to established diagnostic assays such as the basophil activation test, the Hoxb8 mast cell activation test demonstrates similar precision.

The strongest association is found between asthma and the risk of attention deficit/hyperactivity disorder, though these links do not equate to causality.

Children with certain atopic conditions, including asthma and common food allergies, were observed to have a higher risk of developing the chronic disorder.

Patients with hereditary angioedema who received sebetralstat earlier had faster complete resolution of their attacks.

Results indicate that sublingual epinephrine can resolve symptoms, including swelling of the face and throat, associated with oral allergy syndrome in minutes.

Though auto-injectors are still considered an appropriate first-line treatment for anaphylaxis, limited evidence exists surrounding their effectiveness in preventing fatal anaphylaxis.

The gold standard of testing for food allergies is an oral food challenge test where patients consume the allergen, such as peanut extract, under supervision.

Oral immunotherapy is a growing area of research that involves ingesting increasing doses of the allergen to desensitize the patient’s immune system.

A recent study found that indoor allergen exposure, including mouse and cockroach allergens, led to an increased risk of respiratory viral infections in children with asthma.

A number of asthma-related emergency room visits are a result of viruses, but certain airborne pollens—notably Cupressaceae and tree pollens—are also contributors.

neffy is an epinephrine nasal spray for the emergency treatment of allergic reactions in adults and pediatric patients.

The approval marks the first oral immunotherapy treatment to mitigate allergic reactions, including anaphylaxis.

The findings also show that skin testing positivity for perennial allergens was higher in patients with childhood-onset asthma compared with those with adult-onset asthma.

The study results also found that exposure to tree canopy area may protect children from asthma development; however, efficacy decreased as weed pollen exposure increased.

Pharmacists can help patients distinguish between food allergies and intolerances, as well as facilitate access to life-saving medications and preventative care.

Proper diagnosis and selection of products is crucial to management of hay fever

Piezo1 is a protein produced by type 2 innate lymphoid cells when activated by an allergen and can limit the immune cell’s activity when triggered by a reaction.

The BLA includes all indications for Xolair, including asthma, chronic rhinosinusitis with nasal polyps, immunoglobulin E-mediated food allergy, and chronic spontaneous urticaria.

AAO-HNSF guideline development group included 17 panel members, including experts from otolaryngology and allergy, those who have knowledge in clinical practice guideline development, and patient representatives.

The data follow the FDA approval of omalizumab for the reduction of allergic reactions, including anaphylaxis, that can occur after exposure to 1 or more foods.

The results were presented as a late-breaking poster presentation at the American Academy of Allergy, Asthma, and Immunology Annual Meeting.